Rockefeller Capital Management L.P. Trims Stock Position in Kenvue Inc. $KVUE

Rockefeller Capital Management L.P. lessened its stake in Kenvue Inc. (NYSE:KVUE) by 76.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 148,932 shares of the company’s stock after selling 486,217 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Kenvue were worth $2,569,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Physician Wealth Advisors Inc. raised its position in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in Kenvue in the 4th quarter worth approximately $26,000. MV Capital Management Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $28,000. Reflection Asset Management acquired a new stake in shares of Kenvue during the 4th quarter worth approximately $32,000. Finally, SBI Securities Co. Ltd. increased its holdings in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.2%

Shares of KVUE stock opened at $19.09 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The company has a market cap of $36.66 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 1.45 and a beta of 0.54. The stock has a 50 day simple moving average of $17.70 and a 200-day simple moving average of $17.65. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 EPS. On average, equities research analysts expect that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.59% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

KVUE has been the subject of several analyst reports. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Citigroup decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. UBS Group lowered their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Finally, Barclays dropped their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.